SEC Form SC 13G filed by Bio-Techne Corp

11/14/24 1:22:36 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TECH alert in real time by email

SC 13G 1 tech13gsep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) BIO-TECHNE CORP (Name of Issuer) COMMON STOCK (Title of Class of Securities) 09073M104 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 9,137,111 6. Shared Voting Power* 0 7. Sole Dispositive Power* 9,424,313 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 9,424,313 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 5.9% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: BIO-TECHNE CORP Item 1(b) Address of Issuer's Principal Executive Offices: #N/A614 MCKINLEY PL N E, MINNEAPOLIS, MN 55413 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. (Price Associates) Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 09073M104 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class Not Applicable Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: November 14, 2024 Signature: /s/ Ellen York Name & Title: Ellen York, Vice President 09/30/2024

Get the next $TECH alert in real time by email

Recent Analyst Ratings for

$TECH

Date	Price Target	Rating	Analyst
9/3/2025	$73.00	Sector Perform → Outperform	RBC Capital Mkts
8/21/2025	$70.00	Neutral → Buy	Citigroup
7/22/2025	$65.00	Overweight	Stephens
7/9/2025	$65.00	Buy	TD Cowen
5/30/2025	$59.00	Overweight	Wells Fargo
4/9/2025		Overweight → Sector Weight	KeyBanc Capital Markets
3/18/2025	$75.00	Outperform	Evercore ISI
2/19/2025	$88.00 → $68.00	Outperform → Neutral	Robert W. Baird

More analyst ratings

SEC Form SC 13G filed by Bio-Techne Corp

11/14/24 1:22:36 PM ET

$TECH

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TECH alert in real time by email

Recent Analyst Ratings for

$TECH

Date	Price Target	Rating	Analyst
9/3/2025	$73.00	Sector Perform → Outperform	RBC Capital Mkts
8/21/2025	$70.00	Neutral → Buy	Citigroup
7/22/2025	$65.00	Overweight	Stephens
7/9/2025	$65.00	Buy	TD Cowen
5/30/2025	$59.00	Overweight	Wells Fargo
4/9/2025		Overweight → Sector Weight	KeyBanc Capital Markets
3/18/2025	$75.00	Outperform	Evercore ISI
2/19/2025	$88.00 → $68.00	Outperform → Neutral	Robert W. Baird

More analyst ratings

SEC Form SC 13G filed by Bio-Techne Corp

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$TECH

SEC Form SC 13G filed by Bio-Techne Corp

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$TECH

$TECH
Press Releases

Bio-Techne Releases First Quarter Fiscal 2026 Results

BIO-TECHNE DECLARES DIVIDEND

AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients

$TECH
Analyst Ratings

Bio-Techne upgraded by RBC Capital Mkts with a new price target

Bio-Techne upgraded by Citigroup with a new price target

Stephens resumed coverage on Bio-Techne with a new price target

$TECH
Insider Trading

Chief Executive Officer Kelderman Kim covered exercise/tax liability with 2,303 shares, decreasing direct ownership by 5% to 48,665 units (SEC Form 4)

CFO Hippel James converted options into 24,704 shares and covered exercise/tax liability with 11,865 shares, increasing direct ownership by 10% to 142,722 units (SEC Form 4)

PRESIDENT, PROTEIN SCIENCES Geist William converted options into 9,911 shares and covered exercise/tax liability with 4,520 shares, increasing direct ownership by 36% to 20,503 units (SEC Form 4)

$TECH
SEC Filings

SEC Form 10-Q filed by Bio-Techne Corp

Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

SEC Form DEFA14A filed by Bio-Techne Corp

$TECH
Financials

Bio-Techne Releases First Quarter Fiscal 2026 Results

BIO-TECHNE DECLARES DIVIDEND

Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results

$TECH
Leadership Updates

Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

$TECH
Large Ownership Changes